Investing News NetworkYour trusted source for investing success

Videos
Companies
Press Releases
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Private Placements
Trending
Trending Articles

Leigh Goehring: Gold's "Massive Bull Market" Just Starting; Uranium and Copper Outlook

13 Canadian Crypto ETFs (Updated 2024)

Could the Silver Price Really Hit $100 per Ounce? (Updated 2024)

10 Top Oil-producing Countries (Updated 2024)

When is the Starlink IPO Date and Can You Invest? (Updated 2024)

How Would a New BRICS Currency Affect the US Dollar? (Updated 2024)

Uranium Stocks: 5 Biggest Companies in 2024

A State-by-State Guide to Cannabis in Australia (Updated 2024)

How Could Trump's US Election Win Affect the Gold Price?

Trending Press Releases

McDermitt PFS Demonstrates Multi-Decade Competitive Source of US Lithium Carbonate

OSISKO METALS EXPANDS LEADERSHIP TEAM AND ANNOUNCES C$100 MILLION BOUGHT DEAL FINANCING

Silver47 Drills 2.48m of 14.95 g/t Gold, 249.50 g/t Silver, 21.97% Zinc, 7.03% Lead, 0.42% Copper at Its Red Mountain Project, Alaska

First Helium Reviewing Potential Follow Up Targets to Leduc Anomaly Drill

SAGA Metals Announces Assay Results from North Wind Iron Ore Project

Sirona Biochem Announces Publication of Groundbreaking Study on TFC-1326 Compound in the Journal of Cosmetic Dermatology

More Press Releases
Trending Companies

Silver47 Exploration

AGA:CC

Purpose Bitcoin ETF

BTCC:CA

Jindalee Lithium

JLL:AU

Syntheia

SYAI:CC
More Companies
Trending Reports

2024 Gold Outlook Report

2024 Lithium Market Outlook

2024 AI Market Outlook Report

2024 Uranium Outlook

More Outlook Reports
Resource
Resource
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Tech
Tech
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Life Science
Life Science
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Gold Price
Silver Price
Copper Price
Oil Price
Uranium
Artificial Intelligence
loader

Cynata Therapeutics

ASX:CYP

Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus.

Press Releases

Cynata’s Cymerus MSCs Ameliorate Cytokine Release Syndrome in Preclinical Study

Cynata Reports Positive Six-Month Data from Cohort A in Phase 1 Trial of CYP-001 in GvHD

Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus. There are currently three active clinical trials taking place using Cymerus technology which are attempting to treat osteoarthritis, respiratory distress, and diabetic foot ulcers.

Interactive Chart

×